Search research articles
Contact Us
Filters
Showing results (301-310 of 359) with videos related to
Page
of 36
Sort By:
Bioconjugate Chemistry
|
April 9, 2021
Synthesis and Comparative <i>In Vivo</i> Evaluation of Site-Specifically Labeled Radioimmunoconjugates for DLL3-Targeted ImmunoPET
Sai Kiran Sharma, Pierre Adumeau, Outi Keinänen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 20, 2022
Radioimmunotherapy Targeting Delta-like Ligand 3 in Small Cell Lung Cancer Exhibits Antitumor Efficacy with Low Toxicity
Kathryn M Tully, Salomon Tendler, Lukas M Carter, et al.
The Lancet. Oncology
|
June 20, 2018
Convection-enhanced delivery for diffuse intrinsic pontine glioma: a single-centre, dose-escalation, phase 1 trial
Mark M Souweidane, Kim Kramer, Neeta Pandit-Taskar, et al.
The Lancet. Oncology
|
May 31, 2024
Production and regulatory issues for theranostics
Francesco Giammarile, Diana Paez, Richard Zimmermann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 15, 2021
ImmunoPET of Ovarian and Pancreatic Cancer with AR9.6, a Novel MUC16-Targeted Therapeutic Antibody
Sai Kiran Sharma, Kyeara N Mack, Alessandra Piersigilli, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
February 20, 2025
IL13Rα2-Targeting Antibodies for Immuno-PET in Solid Malignancies
Leah Gajecki, Irina V Lebedeva, Yu-Rou Liao, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
August 14, 2019
Biodistribution and Dosimetry of Intraventricularly Administered <sup>124</sup>I-Omburtamab in Patients with Metastatic Leptomeningeal Tumors
Neeta Pandit-Taskar, Pat B Zanzonico, Kim Kramer, et al.
The Lancet. Oncology
|
March 7, 2021
Medical imaging and nuclear medicine: a Lancet Oncology Commission
Hedvig Hricak, May Abdel-Wahab, Rifat Atun, et al.
Neuro-Oncology
|
February 19, 2025
Phase 1 dose-escalation trial using convection-enhanced delivery (CED) of radio-immunotheranostic 124I-Omburtamab for diffuse intrinsic pontine glioma (DIPG)
Mark M Souweidane, Evan D Bander, Pat Zanzonico, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 5, 2020
Safety and Feasibility of PARP1/2 Imaging with <sup>18</sup>F-PARPi in Patients with Head and Neck Cancer
Heiko Schöder, Paula Demétrio De Souza França, Reiko Nakajima, et al.
Page
of 36
Search research articles
Search
Showing results (301-310 of 359) with videos related to
Sort By:
Page
of 36
Bioconjugate Chemistry
|
April 9, 2021
Synthesis and Comparative <i>In Vivo</i> Evaluation of Site-Specifically Labeled Radioimmunoconjugates for DLL3-Targeted ImmunoPET
Sai Kiran Sharma, Pierre Adumeau, Outi Keinänen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 20, 2022
Radioimmunotherapy Targeting Delta-like Ligand 3 in Small Cell Lung Cancer Exhibits Antitumor Efficacy with Low Toxicity
Kathryn M Tully, Salomon Tendler, Lukas M Carter, et al.
The Lancet. Oncology
|
June 20, 2018
Convection-enhanced delivery for diffuse intrinsic pontine glioma: a single-centre, dose-escalation, phase 1 trial
Mark M Souweidane, Kim Kramer, Neeta Pandit-Taskar, et al.
The Lancet. Oncology
|
May 31, 2024
Production and regulatory issues for theranostics
Francesco Giammarile, Diana Paez, Richard Zimmermann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 15, 2021
ImmunoPET of Ovarian and Pancreatic Cancer with AR9.6, a Novel MUC16-Targeted Therapeutic Antibody
Sai Kiran Sharma, Kyeara N Mack, Alessandra Piersigilli, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
February 20, 2025
IL13Rα2-Targeting Antibodies for Immuno-PET in Solid Malignancies
Leah Gajecki, Irina V Lebedeva, Yu-Rou Liao, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
August 14, 2019
Biodistribution and Dosimetry of Intraventricularly Administered <sup>124</sup>I-Omburtamab in Patients with Metastatic Leptomeningeal Tumors
Neeta Pandit-Taskar, Pat B Zanzonico, Kim Kramer, et al.
The Lancet. Oncology
|
March 7, 2021
Medical imaging and nuclear medicine: a Lancet Oncology Commission
Hedvig Hricak, May Abdel-Wahab, Rifat Atun, et al.
Neuro-Oncology
|
February 19, 2025
Phase 1 dose-escalation trial using convection-enhanced delivery (CED) of radio-immunotheranostic 124I-Omburtamab for diffuse intrinsic pontine glioma (DIPG)
Mark M Souweidane, Evan D Bander, Pat Zanzonico, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 5, 2020
Safety and Feasibility of PARP1/2 Imaging with <sup>18</sup>F-PARPi in Patients with Head and Neck Cancer
Heiko Schöder, Paula Demétrio De Souza França, Reiko Nakajima, et al.
Page
of 36